SCHEMBL3522253

SCHEMBL3522253

COC(=O)c1c(OC)c(Br)cc2ncc(-c3ccc(F)c(F)c3)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
KMO O15229 1/20 0.36
PARP1 P09874 1/20 0.35
GRIN2B Q13224 5/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
NEK2 P51955 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C9 P11712 1/20 0.34
SYK P43405 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
RAB9A P51151 1/20 0.34
KIT P10721 1/20 0.34
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518253 0.92 PDGFRB (0.39) PDGFRBPDGFRAMEN1KMT2AKMO
SCHEMBL3758623 0.89 NPC1 (0.41) PDGFRBPDGFRAMEN1KMT2AJAK2
SCHEMBL3518631 0.85 SMN1; SMN2 (0.45) PDGFRBMEN1KMT2APARP1CYP2C9
SCHEMBL3757203 0.82 ALPL (0.44) JAK2JAK1KMOGRIN2BTSHR
SCHEMBL3520500 0.80 PDGFRB (0.40) PDGFRBPDGFRAMEN1KMT2AKMO
SCHEMBL3536173 0.79 HPGD (0.39) PDGFRBPDGFRAJAK2JAK1PARP1
SCHEMBL3519670 0.77 KMO (0.44) KMOGRIN2BCYP2C9
SCHEMBL3518053 0.75 RPS6KB1 (0.39) PDGFRBPDGFRAMEN1KMT2AJAK2
SCHEMBL3517937 0.74 TSHR (0.37) MEN1KMT2ATSHRHTTHPGD
SCHEMBL3520040 0.74 ACLY (0.41) PDGFRBPDGFRAMEN1KMT2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PDGFRB 975/4885PDGFRA 639/4885MEN1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.